Carbachol

Drug class: Antineoplastic Agents

Usage of Carbachol

Open-Angle Glaucoma

Reduction of elevated intraocular pressure (IOP) in patients with primary, open-angle (chronic simple, noncongestive) glaucoma.

Used mainly in patients refractory or hypersensitive to pilocarpine.

May use concomitantly with sympathomimetic agents, β-adrenergic blocking agents, or carbonic anhydrase inhibitors.

Ocular Surgery

Production of miosis during surgery on the anterior chamber of the eye (e.g., cataract extraction, keratoplasty, peripheral iridectomy, cyclodialysis).

Reduction of the intensity of IOP elevation for the first 24 hours after cataract surgery.

Intraocular acetylcholine generally preferred.

Angle-Closure Glaucoma

Reduction of IOP in the emergency treatment of acute (congestive) angle-closure glaucoma† [off-label] prior to surgery.

Pilocarpine generally preferred.

Ophthalmologic Examinations

Production of miosis to counteract mydriatic effects of sympathomimetic agents (e.g., hydroxyamphetamine, phenylephrine) after ophthalmoscopic examinations† [off-label] in glaucoma patients.

Pilocarpine generally preferred.

Relate drugs

How to use Carbachol

Administration

Ophthalmic Administration

Administer ophthalmic topical solution to the conjunctival sac; do not inject.

Administer intraocular injection by injection into the anterior chamber.

Topical Solution

Remove contact lenses before instilling solution.

To minimize adverse effects, begin with a low concentration and increase gradually as needed. Additionally, instill daily dose or one of the daily doses at bedtime.

Following topical instillation, apply finger pressure on the lacrimal sac for 1–2 minutes to minimize drainage into nose and throat and reduce risk of absorption and systemic reactions. Remove excess solution around the eye with a tissue and rinse off any medication on hands immediately.

Intraocular Injection

Instill into anterior chamber of the eye before or after securing sutures, following the manufacturer’s directions. Vials are for single-dose use only; discard unused portion.

Dosage

Adjust concentration and frequency of solution instillation according to patient requirements and response, as determined by tonometric readings before and during therapy.

In patients with heavily pigmented irides, higher solution concentrations may be required.

Adults

Open-Angle Glaucoma Ophthalmic Topical

1–2 drops of 1.5–3% topical solution up to 3 times daily.

Ocular Surgery Intraocular

Inject ≤0.5 mL of a 0.01% solution.

Prescribing Limits

Adults

Ocular Surgery Intraocular

Maximum: 0.5 mL of a 0.01% injection.

Special Populations

No special population dosage recommendations at this time.

Warnings

Contraindications

  • Known hypersensitivity to carbachol or any ingredient in the formulation.
  • Conditions in which pupillary constriction is undesirable (e.g. acute iritis, pupillary block).

    • Warnings/Precautions

    Warnings

    Systemic Toxicity

    Systemic reactions (e.g., salivation, syncope, cardiac arrhythmia, epigastric distress, headache, vomiting, asthma, hypotension, diarrhea, urinary urgency, increased sweating) reported rarely after topical application or intraocular injection; usually occur only with very frequent administration.

    Use cautiously in patients with acute cardiac failure, bronChial asthma, active peptic ulcer, hyperthyroidism, GI spasm, urinary tract obstruction, Parkinson’s disease, recent MI, or systemic hypertension or hypotension.

    Use topical solution cautiously in presence of corneal abrasion to avoid excessive penetration and systemic toxicity.

    If systemic symptoms occur, discontinue drug, at least temporarily.

    Ocular Toxicities

    Retinal detachment reported rarely; use with extreme caution, if at all, in patients with a history or risk of retinal detachment, especially if young or aphakic. Carefully examine retinal periphery at least annually to detect an impending detachment.

    Intraocular injection: Corneal clouding, persistent bullous keratopathy, retinal detachment, and postoperative iritis reported following cataract extraction in some patients.

    Sensitivity Reactions

    Hypersensitivity

    Allergic conjunctivitis, dermatitis, or keratitis reported occasionally with miotics; usually alleviated by changing to another miotic. In some instances, allergic reactions may be caused by preservatives in the preparations.

    Discontinue the drug if sensitivity develops or if original irritation persists or increases.

    General Precautions

    Ocular Effects (Topical Solution)

    Possible spasm of accommodation and poor vision in dim light, particularly in geriatric patients and patients with lens opacities. (See Advice to Patients.)

    Adverse effects often subside after first few days of therapy or if drug is temporarily discontinued. (See Administration under Dosage and Administration.)

    Possible transient increase in IOP even when the angle is open. In some patients with angle-closure glaucoma receiving miotics, may increase IOP and precipitate acute attacks.

    Possible lens opacities and cataracts; lens opacities may regress if therapy discontinued early in development; however, cataracts are often progressive.

    Regular slit-lamp examinations recommended; discontinue therapy, at least temporarily, if iris cysts, iritis, synechiae, or lens opacities occur.

    Specific Populations

    Pregnancy

    Category C.

    Lactation

    Not known whether carbachol is distributed into milk. Use with caution.

    Pediatric Use

    Safety and efficacy not established.

    Geriatric Use

    Reduced visual acuity in dim light is common in geriatric patients. (See Ocular Effects [Topical Solution] under Cautions.)

    Common Adverse Effects

    Topical solution: Ocular irritation (burning or discomfort), lacrimation, temporal or periorbital headache, painful ciliary or accommodative spasm, blurred vision or myopia, conjunctival vascular congestion, poor vision in dim light.

    What other drugs will affect Carbachol

    Specific Drugs

    Drug

    Interaction

    Comments

    Miotics, anticholinesterase

    Possible antagonism

    Concomitant use of miotics not recommended; unresponsiveness to both drugs may develop

    Increased risk of allergic reactions and toxicity

    Ocular hypotensive agents (e.g., carbonic anhydrase inhibitors, topical epinephrine, topical timolol)

    Additive IOP lowering effects

    Used to therapeutic advantage

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords